Does the fixed‑dose combination Teldy (tenofovir disoproxil fumarate, lamivudine, dolutegravir) for HIV prophylaxis interact with amoxicillin/clavulanic acid (Co‑amoxiclav) and oral fluconazole?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No Clinically Significant Drug Interactions Between Teldy and Co-Amoxiclav or Fluconazole

Teldy (tenofovir disoproxil fumarate/lamivudine/dolutegravir) can be safely co-administered with both Co-amoxiclav (amoxicillin/clavulanic acid) and oral fluconazole without dose adjustments or significant safety concerns.

Drug Interaction Analysis

Dolutegravir and Fluconazole

The available evidence demonstrates no drug interactions between dolutegravir and fluconazole 1. Dolutegravir is not metabolized by CYP3A4, CYP2C9, or CYP2C19—the primary enzymes that fluconazole inhibits 2. While fluconazole is a moderate CYP3A4 inhibitor and strong CYP2C19 inhibitor, dolutegravir's metabolism occurs through UGT1A1-mediated glucuronidation, making it unaffected by fluconazole's enzyme inhibition profile.

Tenofovir/Lamivudine and Fluconazole

No interactions exist between tenofovir disoproxil fumarate or lamivudine and fluconazole 1, 3. These nucleoside reverse transcriptase inhibitors (NRTIs) are eliminated primarily through renal excretion and do not undergo significant hepatic metabolism via the cytochrome P450 system that fluconazole affects.

Co-Amoxiclav Interactions

Co-amoxiclav (amoxicillin/clavulanic acid) has no documented interactions with any component of Teldy. Beta-lactam antibiotics like amoxicillin are not metabolized through cytochrome P450 pathways and do not interact with antiretroviral medications through pharmacokinetic mechanisms.

Clinical Recommendations

  • Continue all three medications concurrently without dose modifications
  • No additional monitoring is required beyond standard HIV prophylaxis follow-up
  • No timing adjustments needed for medication administration—all can be taken together or separately as convenient

Important Caveats

While fluconazole can cause QT prolongation 2, this is primarily a concern with high-dose fluconazole (≥800 mg) or in patients with pre-existing cardiac risk factors (hypokalemia, structural heart disease, concurrent QT-prolonging medications). For typical fluconazole dosing (150-400 mg), this risk is minimal and does not contraindicate use with Teldy.

The enzyme-inhibiting effects of fluconazole persist 4-5 days after discontinuation due to its long half-life 2, but this is irrelevant for Teldy components given the absence of metabolic interactions.

Related Questions

What are the current Indian National AIDS Control Organisation recommendations for first‑line and second‑line antiretroviral therapy in treatment‑naïve HIV‑positive adults, including the preferred regimen, alternatives for renal impairment, monitoring schedule, treatment‑failure criteria, and special considerations for tuberculosis co‑infection and pregnancy?
What are the choices for post-exposure prophylaxis (PEP)?
What are the key considerations for patients taking Dovato (dolutegravir and lamivudine)?
What is the current first-line Antiretroviral Therapy (ART) regimen in India for the treatment of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS)?
What is the appropriate evaluation and management for a 29‑year‑old person living with HIV on Dovato (dolutegravir + lamivudine) who presents with a two‑week history of cough, vomiting, and tachycardia?
What investigations are indicated for a 9-year-old with a three-month history of peripheral edema, dyspnea, and leg pain?
What are the recommended citalopram dosing regimens for adults, elderly patients, patients with hepatic impairment, and adolescents?
In a patient with known heart failure with reduced ejection fraction who is currently pregnant, which heart failure medications should be stopped and which should be continued?
I am a 47-year-old man with hair loss; can you interpret my laboratory results, including CBC, iron studies, vitamin D level, thyroid function, liver enzymes, and ANA findings?
How should dialysate sodium concentration be managed in a hemodialysis patient with persistent intradialytic hypertension?
In a pregnant patient with rheumatic heart disease, severe mitral regurgitation and tricuspid regurgitation, mild global hypokinesia, and left ventricular ejection fraction of 50% who is on standard heart‑failure therapy, which medications should be discontinued?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.